ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

NURO NeuroMetrix Inc

4,55
0,08 (1,79%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
NeuroMetrix Inc NURO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,08 1,79% 4,55 06:00:07
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,45 4,28 4,45 4,30 4,47
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
19.4.202414:00GLOBENeuroMetrix Announces Steps Taken to Enhance Shareholder..
14.3.202414:00GLOBENeuroMetrix Announces Publication of Study Demonstrating..
13.3.202414:00GLOBENeuroMetrix announces that over 2000 patients with..
06.3.202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202422:12EDGAR2Form SC 13D/A - General statement of acquisition of..
01.3.202423:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202422:45EDGAR2Form 8-K/A - Current report: [Amend]
27.2.202422:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
26.2.202423:41EDGAR2Form SC 13D - General statement of acquisition of beneficial..
22.2.202413:15EDGAR2Form 8-K - Current report
22.2.202413:00GLOBENeuroMetrix Reports Q4 and Full Year 2023 Business..
20.2.202420:49EDGAR2Form SCHEDULE 13G - Statement of acquisition of beneficial..
15.2.202415:00GLOBENeuroMetrix, Inc. Announces Date for Fourth Quarter and Full..
13.2.202415:00GLOBENeuroMetrix Announces Review of Strategic Options to Promote..
12.12.202315:00GLOBENeuroMetrix Reports Encouraging Results from Pilot Clinical..
05.12.202315:00GLOBENeuroMetrix Announces Peer-Reviewed Publication of Phase 2..
20.11.202315:33EDGAR2Form 8-K - Current report
20.11.202315:00GLOBENeuroMetrix Announces One-for-Eight Reverse Stock Split
26.10.202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26.10.202313:11EDGAR2Form 8-K - Current report
26.10.202313:00GLOBENeuroMetrix Reports Q3 2023 Business Highlights
23.10.202317:13GLOBENeuroMetrix, Inc. Announces Date for Third Quarter 2023..
20.10.202320:59EDGAR2Form 8-K - Current report
02.10.202315:00GLOBENeuroMetrix and the National Fibromyalgia Association to..
11.9.202313:59EDGAR2Form DEF 14A - Other definitive proxy statements
11.8.202323:11EDGAR2Form 8-K - Current report
05.8.202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.8.202300:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.8.202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.8.202323:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.7.202322:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.7.202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27.7.202313:24EDGAR2Form 8-K - Current report
27.7.202313:00GLOBENeuroMetrix Reports Q2 2023 Business Highlights
20.7.202319:00GLOBENeuroMetrix, Inc. Announces Date for Second Quarter 2023..
11.7.202315:00GLOBENeuroMetrix Announces Sales Force Expansion for Quell..
28.6.202315:00GLOBERecent Publications Demonstrate Utility of DPNCheck® for..
07.6.202315:00GLOBEDiabetic Peripheral Neuropathy Screening That Includes..
31.5.202315:00GLOBEQuell® Demonstrates Encouraging Clinical Trial Results in..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock